Özel Hasta Populasyonlarında Onkolojik Tedaviye Bağlı Kardiyovasküler Komplikasyonlar

Lipshultz SE, Sambatakos P, Maguire M, et al. Cardiotoxicity and cardioprotection in childhood cancer. Acta Haematol. 2014;132:391–9.

Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128: 1927–95.

Van der Pal HJ, Van Dalen EC, Van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012;30:1429–37.

Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010;28:1308–1315.

Dillenburg RF, Nathan P, Mertens L. Educational paper: decreasing the burden of cardiovascular dis- ease in childhood cancer survivors: an update for the pediatrician. Eur J Pediatr. 2013;172:1149–60.

Gudmundsdottir T, Winther JF, de Fine Licht S, et al. ALiCCS study group. Cardiovascular disease in adult life after childhood cancer in Scandinavia: a population-based cohort study of 32,308 one-year survi- vors. Int J Cancer 2015;137:1176–1186.

Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16:e123–36.

Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow- up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55:1145–52.

Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007;8:1039–58.

VejpongsaP,YehETH.Preventionofanthracycline-inducedcardiotoxicity:challengesandopportunities. J Am Coll Cardiol. 2014;64:938–45.

Kremer LCM, van Dalen EC. Dexrazoxane in children with cancer: from evidence to practice. J Clin Oncol. 2015;33:2594–6. doi:10.1200/JCO.2015.61.7928.

Chow EJ, Asselin BL, Doody DR, et al. Late mortality after dexrazoxane treatment: a report from the Children’s Oncology Group. J Clin Oncol. 2015. doi:10.1200/JCO.2014.59.4473.

Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11:950–61.

VanDalenEC,CaronHN,DickinsonHO, et al.Cardioprotectiveinterventionsforcancerpatients receiving anthracyclines. Cochrane Database Syst Rev. 2011. CD003917. doi:10.1002/14651858. CD003917.pub4

Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicentre study. J Clin Oncol. 2011;29(25):3457–65.

Extermann M, Aapro M, Bernabei R, et al. Use of the comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55(3):241–55.

SogaardM,ThomsenRW,BossenKS, et al. Theimpactofcomorbidityoncancer survival: a review. Clin Epidemiol. 2013;5:3–29.

Luciani AB, Battisti N, Romanato G, et al. The assessment of chemotherapy risk in elderly cancer patients: validation of the CRASH score in an Italian cohort. J Clin Oncol. 2015; 33 (suppl; abstr e20521).

MaggioreRJ,DaleW,GrossCP,FengT,etal. Polypharmacy andpotentiallyinappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related tox icity and hospitalization during treatment. J Am Geriatr Soc. 2014;62:1505–1512 ([Epub 2014/07/22]).

Zauderer M, Patil S, Hurria A. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat. 2009;117:205–10.

Giordano SH, Pinder M, Duan Z, et al. Congestive heart failure (CHF) in older women treated with anthracycline (A) chemotherapy (C). J Clin Oncol. 2006; 24 (abstr 521)

Balducci L, Beghe C. Pharmacology of chemotherapy in the older cancer patient. Cancer Control. 1999;6:466–70.

FumoleauP,RochéH,KerbratP,etal.Longtermcardiactoxicity after adjuvant epirubicin basedche-motherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006;17:85–92.

Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outco- mes. J Clin Oncol 2010;28:683–689.

Gziri MM, Debieve F, de Catte L, et al. Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function. Acta Obstet Gynecol Scand 2012;91:1465–1468.

Van Calsteren K, Verbesselt R, Beijnen J, et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol 2010;119:594–600.

Cardonick E, Dougherty R, Grana G, et al. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J 2010;16:76–82.